Literature DB >> 32687431

Role of the RNA-binding protein La in cancer pathobiology.

Gunhild Sommer1, Tilman Heise1.   

Abstract

RNA-binding proteins are important regulators of RNA metabolism and are of critical importance in all steps of the gene expression cascade. The role of aberrantly expressed RBPs in human disease is an exciting research field and the potential application of RBPs as a therapeutic target or a diagnostic marker represents a fast-growing area of research.Aberrant overexpression of the human RNA-binding protein La has been found in various cancer entities including lung, cervical, head and neck, and chronic myelogenous leukaemia. Cancer-associated La protein supports tumour-promoting processes such as proliferation, mobility, invasiveness and tumour growth. Moreover, the La protein maintains the survival of cancer cells by supporting an anti-apoptotic state that may cause resistance to chemotherapeutic therapy.The human La protein represents a multifunctional post-translationally modified RNA-binding protein with RNA chaperone activity that promotes processing of non-coding precursor RNAs but also stimulates the translation of selective messenger RNAs encoding tumour-promoting and anti-apoptotic factors. In our model, La facilitates the expression of those factors and helps cancer cells to cope with cellular stress. In contrast to oncogenes, able to initiate tumorigenesis, we postulate that the aberrantly elevated expression of the human La protein contributes to the non-oncogenic addiction of cancer cells. In this review, we summarize the current understanding about the implications of the RNA-binding protein La in cancer progression and therapeutic resistance. The concept of exploiting the RBP La as a cancer drug target will be discussed.

Entities:  

Keywords:  Bcl2; BiP; CCND1; IRES; LARP; La autoantigen; La protein; La-related proteins; La/SSB; Laminin B1; Mdm2; PTM; RBP; RNA-binding; SUMO; TOP mRNAs; XIAP; anti-apoptotic; cancer; cyclin D1; invasion; non-oncogenic addiction; posttranslational modification; proliferation; translation; tumour-promoting

Year:  2020        PMID: 32687431      PMCID: PMC7928073          DOI: 10.1080/15476286.2020.1792677

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  238 in total

1.  Detailed analysis of the phosphorylation of the human La (SS-B) autoantigen. (De)phosphorylation does not affect its subcellular distribution.

Authors:  C H Broekhuis; G Neubauer; A van der Heijden; M Mann; C G Proud; W J van Venrooij; G J Pruijn
Journal:  Biochemistry       Date:  2000-03-21       Impact factor: 3.162

2.  The La antigen inhibits the activation of the interferon-inducible protein kinase PKR by sequestering and unwinding double-stranded RNA.

Authors:  Q Xiao; T V Sharp; I W Jeffrey; M C James; G J Pruijn; W J van Venrooij; M J Clemens
Journal:  Nucleic Acids Res       Date:  1994-07-11       Impact factor: 16.971

Review 3.  SUMO and the robustness of cancer.

Authors:  Jacob-Sebastian Seeler; Anne Dejean
Journal:  Nat Rev Cancer       Date:  2017-01-30       Impact factor: 60.716

Review 4.  The role of the La autoantigen in internal initiation.

Authors:  G J Belsham; N Sonenberg; Y V Svitkin
Journal:  Curr Top Microbiol Immunol       Date:  1995       Impact factor: 4.291

5.  La autoantigen is necessary for optimal function of the poliovirus and hepatitis C virus internal ribosome entry site in vivo and in vitro.

Authors:  Mauro Costa-Mattioli; Yuri Svitkin; Nahum Sonenberg
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

Review 6.  Protein kinase CK2 in health and disease: CK2: a key player in cancer biology.

Authors:  J H Trembley; G Wang; G Unger; J Slaton; K Ahmed
Journal:  Cell Mol Life Sci       Date:  2009-06       Impact factor: 9.261

7.  AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression.

Authors:  Joseph F Gera; Ingo K Mellinghoff; Yijiang Shi; Matthew B Rettig; Chris Tran; Jung-hsin Hsu; Charles L Sawyers; Alan K Lichtenstein
Journal:  J Biol Chem       Date:  2003-10-23       Impact factor: 5.157

8.  The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma.

Authors:  O Govaere; M Petz; J Wouters; Y-P Vandewynckel; E J Scott; B Topal; F Nevens; C Verslype; Q M Anstee; H Van Vlierberghe; W Mikulits; T Roskams
Journal:  Oncogene       Date:  2017-08-07       Impact factor: 9.867

9.  Short stretches of rare codons regulate translation of the transcription factor ZEB2 in cancer cells.

Authors:  W R Wan Makhtar; G Browne; A Karountzos; C Stevens; Y Alghamdi; A R Bottrill; S Mistry; E Smith; M Bushel; J H Pringle; A E Sayan; E Tulchinsky
Journal:  Oncogene       Date:  2017-08-07       Impact factor: 9.867

10.  LARP4 mRNA codon-tRNA match contributes to LARP4 activity for ribosomal protein mRNA poly(A) tail length protection.

Authors:  Sandy Mattijssen; Aneeshkumar G Arimbasseri; James R Iben; Sergei Gaidamakov; Joowon Lee; Markus Hafner; Richard J Maraia
Journal:  Elife       Date:  2017-09-12       Impact factor: 8.140

View more
  6 in total

Review 1.  LARP1 and LARP4: up close with PABP for mRNA 3' poly(A) protection and stabilization.

Authors:  Sandy Mattijssen; Guennadi Kozlov; Bruno D Fonseca; Kalle Gehring; Richard J Maraia
Journal:  RNA Biol       Date:  2021-01-31       Impact factor: 4.652

2.  RNA-Binding Protein La Mediates TGFβ-Induced Epithelial to Mesenchymal Transition and Cancer Stem Cell Properties.

Authors:  Tilman Heise; Gunhild Sommer
Journal:  Cancers (Basel)       Date:  2021-01-19       Impact factor: 6.639

3.  Elevated expression of the RNA-binding motif protein 43 predicts poor prognosis in esophageal squamous cell carcinoma.

Authors:  Yong Li; Li-Li Liu; Rui Hu; Qi Sun; Xiao-Bo Wen; Rong-Zhen Luo; Shu-Mei Yan
Journal:  Int J Clin Oncol       Date:  2021-08-16       Impact factor: 3.402

4.  A Novel circRNA hsa_circRNA_002178 as a Diagnostic Marker in Hepatocellular Carcinoma Enhances Cell Proliferation, Invasion, and Tumor Growth by Stabilizing SRSF1 Expression.

Authors:  Jing Li; Ting Han; Zhenzhen Li; Hongmei Han; Yingchun Yin; Baohua Zhang; Hengming Zhang; Luan Li
Journal:  J Oncol       Date:  2022-08-27       Impact factor: 4.501

5.  La protein regulates protein expression by binding with the mRNAs of target genes and participates the pathological process of ovarian cancer.

Authors:  Xuan Huang; Jialei Zhu; Yueyan Li; Yang Yu; Jing Tang
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

6.  Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models.

Authors:  Vasilios Liapis; William Tieu; Nicole L Wittwer; Tessa Gargett; Andreas Evdokiou; Prab Takhar; Stacey E Rudd; Paul S Donnelly; Michael P Brown; Alexander H Staudacher
Journal:  Mol Imaging Biol       Date:  2021-07-06       Impact factor: 3.488

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.